Loading research and source information…
Alzheimer’s disease · Drug research
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Evidence 1Content updated Oct 27, 2026 · Sources last checked Oct 27, 2026
Inclusion Criteria: * Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months * MMSE score of 20 to 28 (inclusive) at baseline * Meet 18F flortaucipir PET scan (central read) criteria - does not apply to safety cohort * Meet 18F florbetapir PET scan (central read) criteria * Have a study partner who will provide written informed consent to participate Exclusion Criteria: * Contraindication to MRI or PET scans * Current treatment with immunoglobulin G (IgG) therapy
This record covers only the linked trial population. This registry-based page does not review FDA approval or labeling.
FDA approval not reviewed here
Alzheimer’s disease
See FDA labeling for the approved population and indication; this page covers the trial population only.
FDA labeling has not been reviewed for this page. This does not mean the treatment is unapproved.
Approval is specific to the indication and population. It does not establish availability, reimbursement or suitability for an individual.
This study is continuing but is no longer enrolling new participants.
Read trial record and posted resultsStudy ages: 60 Years to 85 Years. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Australia, Canada, Czechia, Japan, Netherlands, Poland, Puerto Rico, United Kingdom, United States.
Primary data collection: Apr 14, 2023 (actual). This is not a results-release date.
Results posted May 20, 2024
Evidence 1registry · Registry metadata is submitted by the sponsor or responsible party and does not independently validate efficacy.
Results are posted in the registry. Outcomes have not been appraised in this record.
Limitations: Outcomes, effect estimates, uncertainty and study quality have not been appraised. Consult original results and publications.
Evidence 1A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
registry · NCT04437511 · Structured source fields
Source date: Aug 26, 2026 · Checked: Oct 27, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Conditions: Alzheimer Disease.
Open original source